News

Aileron Therapeutics Reports Third Quarter 2019 Results

Announced positive interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer’s IBRANCE® (palbociclib) for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification Presented new nonclinical data showing ALRN-6924 reduced chemotherapy-related toxicities (“myelopreservation”) in cellular studies and mouse models of cancer without…

Read More
Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th

Nonclinical research showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells without inhibiting the anti-cancer activity of chemotherapy. ALRN-6924 could enable a precision-medicine strategy to prevent the toxic side effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer. WATERTOWN, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) — Aileron…

Read More
Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference

Nonclinical research results show that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells and enhanced the anti-cancer activity of chemotherapy. ALRN-6924 could enable a precision-medicine strategy to prevent the toxic side effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer. WATERTOWN, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE)…

Read More
Aileron Therapeutics to Report Third Quarter 2019 Financial Results on November 7th

WATERTOWN, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) — Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today announced that the Company will host a conference call and webcast at 8:30 a.m. ET on Thursday, November 7, 2019 to report its third quarter 2019 financial results and provide a corporate update. To access the live conference call, please…

Read More